BRAF and melanoma: BRAF inhibitors, vemurafenib and dabrafenib, have been approved for use in melanoma patients who are BRAF V600E/V600K mutation carriers, these agents have been shown to significantly improve survival in BRAF-mutated melanoma patients [5, 6].